Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Protagonist Therapeutics Q2 EPS $(0.69) Down From $(0.59) YoY

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.69) per share. This is a 16.95 percent decrease over losses of $(0.59) per share from the same period last year.

byBill Haddad

August 4, 2021

1 minute read

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.69) per share. This is a 16.95 percent decrease over losses of $(0.59) per share from the same period last year.

Morgan Stanley Maintains Equal-Weight on Altus Power, Raises Price Target to $14

By Benzinga Newsdesk

Today, 11:59 AM

Morgan Stanley analyst Stephen Byrd maintains Altus Power (NYSE:AMPS) with a Equal-Weight and raises the price target from $12.5 to $14.

AMPS

Evercore ISI Group Maintains In-Line on Netflix, Lowers Price Target to $245

By Benzinga Newsdesk

Today, 11:59 AM

Evercore ISI Group analyst Mark Mahaney maintains Netflix (NASDAQ:NFLX) with a In-Line and lowers the price target from $300 to $245.

NFLX

Helbiz Extends Partnership With Leasys For 2,950 New Scooters For Italian Market

By Benzinga Newsdesk

Today, 11:59 AM

Helbiz (NASDAQ:HLBZ), a global leader in micro-mobility and the first in its sector to be listed on Nasdaq, is extending its partnership with Leasys S.p.A of the Stellantis Group, as part of their

HLBZ